Medison is a global pharma company focused on providing access to highly innovative therapies to patients in international markets. Medison is the first to create an international commercialization platform for highly innovative therapies, helping to save and improve lives by making the best available novel treatments accessible to patients in international markets. Medison has a track record of multi-territorial partnerships with leading pharmaceutical and biotech companies seeking to expand their global reach.

Our Hepatology focused product: BYLVAY (odevixibat), the first Health Canada-approved treatment of pruritus in both progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).

To learn more visit www.medisonpharma.com